
Over eleven months, Laver Stim engineered robust genomic data processing features for the hartwigmedical/hmftools repository, focusing on variant analysis, BAM file manipulation, and copy-number workflows. Leveraging Java and Python, Laver designed and refactored core modules to support complex tasks such as HLA alt contig remapping, chimerism detection, and segment-aware copy-number analysis. He implemented scalable end-to-end testing, optimized algorithms for performance, and enhanced data validation and reporting, particularly for clinical genomics pipelines. His work emphasized maintainability and reliability, with comprehensive test coverage and modular code organization, resulting in a stable, production-ready toolchain for high-throughput genomic analysis.

October 2025 monthly summary for hartwigmedical/hmftools focusing on business value and technical achievements. Delivered three feature enhancements that strengthen the accuracy, configurability, and reliability of the Cobalt analysis and fragment metrics, enabling better data-driven decisions and downstream impact.
October 2025 monthly summary for hartwigmedical/hmftools focusing on business value and technical achievements. Delivered three feature enhancements that strengthen the accuracy, configurability, and reliability of the Cobalt analysis and fragment metrics, enabling better data-driven decisions and downstream impact.
September 2025 monthly summary for hartwigmedical/hmftools focused on strengthening Cobalt reliability and performance. Delivered comprehensive end-to-end testing across whole-genome, germline-only, and tumor-germline analyses, including low-coverage BAMs and depth-0 scenarios, with test maintenance and selective ignore markers to keep the suite robust and maintainable. Implemented region exclusion for targeted masking of GC-related biases through optional excluded regions and Ig pseudo gene exclusions. Standardized Cobalt ratio file naming to align with existing filename generation. Fixed critical germline status logic for zero normal ratio to ensure correct downstream predictions. Refactored Segmenter to separate testing concerns and optimize cost calculation, delivering measurable performance improvements. Completed several maintenance-related changes to improve consistency and reliability of analyses.
September 2025 monthly summary for hartwigmedical/hmftools focused on strengthening Cobalt reliability and performance. Delivered comprehensive end-to-end testing across whole-genome, germline-only, and tumor-germline analyses, including low-coverage BAMs and depth-0 scenarios, with test maintenance and selective ignore markers to keep the suite robust and maintainable. Implemented region exclusion for targeted masking of GC-related biases through optional excluded regions and Ig pseudo gene exclusions. Standardized Cobalt ratio file naming to align with existing filename generation. Fixed critical germline status logic for zero normal ratio to ensure correct downstream predictions. Refactored Segmenter to separate testing concerns and optimize cost calculation, delivering measurable performance improvements. Completed several maintenance-related changes to improve consistency and reliability of analyses.
August 2025 performance highlights for hartwigmedical/hmftools: Delivered significant data-processing enhancements and a stronger testing base across Purple and Cobalt workflows. Implemented segment-aware copy-number workflows, expanded end-to-end testing and GC filtering, and introduced a Java PCF segmentation engine, enabling scalable, accurate copy-number analyses. Fixed core reliability issues, improved test data retrieval, and stabilized compilation, reducing production risk and accelerating release readiness.
August 2025 performance highlights for hartwigmedical/hmftools: Delivered significant data-processing enhancements and a stronger testing base across Purple and Cobalt workflows. Implemented segment-aware copy-number workflows, expanded end-to-end testing and GC filtering, and introduced a Java PCF segmentation engine, enabling scalable, accurate copy-number analyses. Fixed core reliability issues, improved test data retrieval, and stabilized compilation, reducing production risk and accelerating release readiness.
July 2025 monthly summary for hartwigmedical/hmftools: Key features delivered, major fixes, and testing improvements across the toolchain. Achieved measurable business value through improvements in targeted sequencing analysis, expanded data output capabilities, and strengthened validation infrastructure.
July 2025 monthly summary for hartwigmedical/hmftools: Key features delivered, major fixes, and testing improvements across the toolchain. Achieved measurable business value through improvements in targeted sequencing analysis, expanded data output capabilities, and strengthened validation infrastructure.
June 2025 monthly summary for hartwigmedical/hmftools: Focused on delivering observable improvements and robustness in chimerism and tumor profiling, with measurable business impact through enhanced observability, improved detection accuracy, and safer handling of tumor-only data scenarios.
June 2025 monthly summary for hartwigmedical/hmftools: Focused on delivering observable improvements and robustness in chimerism and tumor profiling, with measurable business impact through enhanced observability, improved detection accuracy, and safer handling of tumor-only data scenarios.
April 2025: Delivered robustness fixes and data-model enhancements across hmftools, increasing variant calling reliability, transcript-level reporting, and pipeline quality. Key outcomes include strengthened reverse-variant calling stability, expanded HGVS range handling, richer transcript-impact data, and added chimerism detection in PURPLE, enabling more accurate clinical reporting and data-driven decisions.
April 2025: Delivered robustness fixes and data-model enhancements across hmftools, increasing variant calling reliability, transcript-level reporting, and pipeline quality. Key outcomes include strengthened reverse-variant calling stability, expanded HGVS range handling, richer transcript-impact data, and added chimerism detection in PURPLE, enabling more accurate clinical reporting and data-driven decisions.
March 2025 monthly summary for hartwigmedical/hmftools: Focused on enabling scalable, robust variant processing with a core refactor of Pave and the introduction of a reverse pave architecture, plus batch processing capabilities and HGVS DNA groundwork. Delivered major module improvements, enhanced testing, and packaging/documentation updates to support maintainability and deployment in production.
March 2025 monthly summary for hartwigmedical/hmftools: Focused on enabling scalable, robust variant processing with a core refactor of Pave and the introduction of a reverse pave architecture, plus batch processing capabilities and HGVS DNA groundwork. Delivered major module improvements, enhanced testing, and packaging/documentation updates to support maintainability and deployment in production.
February 2025 monthly summary for hartwigmedical/hmftools. Focused on delivering test scaffolding for complex delins variants, comprehensive refactoring to improve structure and readiness for upcoming features, and multi-faceted progress on deletions, duplications, and insertions with strand-aware handling. Also advanced variant handling reliability, crash prevention, and documentation updates to reflect pave module changes. These efforts increased test coverage, stability, and scalability of the variant processing pipeline, enabling faster, safer deployments in clinical genomics workflows.
February 2025 monthly summary for hartwigmedical/hmftools. Focused on delivering test scaffolding for complex delins variants, comprehensive refactoring to improve structure and readiness for upcoming features, and multi-faceted progress on deletions, duplications, and insertions with strand-aware handling. Also advanced variant handling reliability, crash prevention, and documentation updates to reflect pave module changes. These efforts increased test coverage, stability, and scalability of the variant processing pipeline, enabling faster, safer deployments in clinical genomics workflows.
January 2025 highlights for hartwigmedical/hmftools focused on strengthening validation, expanding feature readiness, and improving maintainability. Delivered expanded test infrastructure and edge-case coverage, initiated SNV output with MNV groundwork, and added reverse-strand support for key variant types. Implemented BAM writer improvements, introduced a multithreading option with removal of a heavy dependency, and undertook code cleanup and module-wide refactoring to enhance maintainability and scalability. Also stabilized the codebase through targeted bug fixes in unmapped reads, unit tests, and codon boundary handling.
January 2025 highlights for hartwigmedical/hmftools focused on strengthening validation, expanding feature readiness, and improving maintainability. Delivered expanded test infrastructure and edge-case coverage, initiated SNV output with MNV groundwork, and added reverse-strand support for key variant types. Implemented BAM writer improvements, introduced a multithreading option with removal of a heavy dependency, and undertook code cleanup and module-wide refactoring to enhance maintainability and scalability. Also stabilized the codebase through targeted bug fixes in unmapped reads, unit tests, and codon boundary handling.
December 2024 monthly summary for hartwigmedical/hmftools. Delivered substantial enhancements to BAM processing for alternative contigs and HLA regions, expanded amino acid variant parsing, and improved documentation for the PAVE tool. These changes improve variant remapping accuracy in complex genomic regions, broaden support for HGVS representations, and strengthen developer and user onboarding through clearer documentation. Key outcomes include completion of end-to-end testing, expanded test coverage, and enforced code quality improvements with a more robust transformation workflow, enabling more reliable downstream analyses and faster integration with clinical pipelines.
December 2024 monthly summary for hartwigmedical/hmftools. Delivered substantial enhancements to BAM processing for alternative contigs and HLA regions, expanded amino acid variant parsing, and improved documentation for the PAVE tool. These changes improve variant remapping accuracy in complex genomic regions, broaden support for HGVS representations, and strengthen developer and user onboarding through clearer documentation. Key outcomes include completion of end-to-end testing, expanded test coverage, and enforced code quality improvements with a more robust transformation workflow, enabling more reliable downstream analyses and faster integration with clinical pipelines.
November 2024 monthly summary for hartwigmedical/hmftools: Delivered HLA alt contig remapping and BAM filtering features. Introduced Remapper to filter BAM records tied to alternative references (starting with HLA) and added AltContigRemapper tool to correctly remap HLA alt contigs using a reference genome. Included a new remapper class, configuration, tests, and resource files to improve genomic analysis accuracy. Laid groundwork for end-to-end unit testing and stabilized builds by addressing a dylib issue observed on another machine, improving CI reliability. This work enhances accuracy of genomic analyses involving alternative references and reduces false positives in downstream variant calling, delivering tangible business value for clinical genomics workflows.
November 2024 monthly summary for hartwigmedical/hmftools: Delivered HLA alt contig remapping and BAM filtering features. Introduced Remapper to filter BAM records tied to alternative references (starting with HLA) and added AltContigRemapper tool to correctly remap HLA alt contigs using a reference genome. Included a new remapper class, configuration, tests, and resource files to improve genomic analysis accuracy. Laid groundwork for end-to-end unit testing and stabilized builds by addressing a dylib issue observed on another machine, improving CI reliability. This work enhances accuracy of genomic analyses involving alternative references and reduces false positives in downstream variant calling, delivering tangible business value for clinical genomics workflows.
Overview of all repositories you've contributed to across your timeline